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Purpose: Non-alcoholic fatty liver disease (NAFLD) in children has become an important public health issue because 
of its high prevalence and severity. Several noninvasive methods for estimating NAFLD are under investigation. 
We aimed to evaluate the usefulness of serum ferritin as a biomarker of severity of pediatric NAFLD patients.
Methods: A total of 64 NAFLD patient were enrolled from Severance Children’s Hospital from March 2010 to February 
2013. Serum ferritin levels, liver related laboratory tests, liver magnetic resonance imaging (MRI) (2-dimensional 
[2D] proton density-fat fraction) and NAFLD severity markers were compared between obese group and overweight 
group. Correlation analyses were performed between serum ferritin and laboratory values including NAFLD severity 
markers.
Results: In obese group, serum ferritin, alanine aminotransferase (ALT), total bilirubin, international normalized ratio 
(INR), MRI 2D proton density-fat fraction, aspartate aminotransferase (AST) to platelet ratio index (APRI) and fib-
rosis-4 (FIB-4) (an index score calculated from platelet count, ALT, AST and age) were significantly higher than those 
of overweight group. NAFLD severity markers, APRI and FIB-4, and liver specific important laboratory values, AST, 
ALT, INR, cholesterol, triglyceride and low density lipoprotein show significant correlation with serum ferritin in NAFLD 
patients. 
Conclusion: Serum ferritin concentrations could be a candidate of useful severity marker in the pediatric NAFLD 
patients. 
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INTRODUCTION
　Non-alcoholic fatty liver disease (NAFLD) repre-
sents a spectrum of liver diseases ranging from hep-
atocellular steatosis to irreversible liver cirrhosis and 
is closely related to obesity and metabolic syndrome 
[1]. Metabolic syndrome is characterized by obesity, 
hyperlipidemia, diabetes mellitus (DM), and insulin 
resistance. In adults, as well as hypertension, obe-
sity, and DM, the frequency of metabolic syndrome 
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is increasing gradually. Metabolic syndrome can be 
manifested as NAFLD in the liver [2-4]. The preva-
lence of NAFLD is also increasing due to the increase 
in the rate of metabolic syndrome. NAFLD is raising 
the morbidity and mortality rates associated with 
the liver [5]. In western countries, the morbidity of 
NAFLD is 20-30% of total adults and 90% of obese 
adults. Moreover, non-alcoholic steatohepatitis (NASH) 
is affecting an estimated 2-3% of the general pop-
ulation and up to 37% of obese individuals [1]. 
Approximately 10% of patients with NAFLD progress 
to NASH, and 8-26% of NASH patients progress to 
cirrhosis [2].
　The prevalence of NAFLD in children and young 
adults is also increasing rapidly. Studies have re-
ported about 3% prevalence of NAFLD in the general 
pediatric population and 53% in obese children [1]. 
Due to the Westernized lifestyle and diet, pediatric 
NAFLD is expected to increase significantly in the fu-
ture globally. Furthermore, NAFLD can have more 
severe influence to children due to longer duration of 
the disease. Therefore, as with adults, the im-
portance of the early diagnosis and proper treatment 
of NAFLD and NASH in children is increasing in or-
der to prevent liver cirrhosis and hepatocellular 
carcinoma.
　NAFLD can be diagnosed after the exclusion of 
other liver diseases and identifying image studies of 
the fatty liver [6]. To diagnose NASH, various meth-
ods―including magnetic resonance imaging (MRI) 
proton density-fat fraction (PDFF), which has been 
actively studied recently―are being used. MRI PDFF 
is a non-invasive and quantitative means of quanti-
fying hepatic steatosis in patients with NAFLD [7]. 
However, the exact cut-off value has yet not been es-
tablished, and the MRI equipment itself is not easily 
obtained due to its high price. Confirmation of the 
disease can be made only by pathology, which is 
characterized as steatosis, lobular inflammation, 
and hepatocellular ballooning [2,8]. However, liver 
biopsy is invasive in children. Furthermore, there is 
the possibility of sampling error of liver biopsy speci-
mens [9]. Therefore, to follow up on the progression 
of NAFLD, repeated liver biopsies are nearly impos-
sible, especially for children. Thus, researchers are 
seeking non-invasive and cost-effective tools for the 
diagnosis of NAFLD and NASH. They are making ef-
forts to develop biological markers to predict the pro-
gression from simple fatty liver to NASH, liver fib-
rosis, cirrhosis, and hepatocellular carcinoma [10]. 
In recent adult studies, serum ferritin levels were re-
ported to be an independent predictor of advanced 
hepatic fibrosis in patients with NAFLD based on its 
correlation with hepatic inflammation and hepatic 
iron storage [10]. Serum ferritin levels are known to 
be elevated in patients with NAFLD and seem to be 
related to insulin resistance and hepatocyte damage 
[11]. So researchers are interested in serum ferritin 
as a biomarker that can reflect the inflammatory 
change of the liver for children as well. In fact, pedia-
tric gastroenterologists are more earnestly seeking 
simple and noninvasive biologic markers for NAFLD. 
If simple and non-invasive biologic markers for 
NAFLD are found, it will be very helpful in disease 
management due to improved compliance of fol-
low-up. Also early detection or screening could be 
possible for the pediatric NAFLD patients who may 
progress to liver cirrhosis. Proper medical treatment 
to the patients could be provided at an appropriate 
time accordingly. We also can expect an additional 
effect that might reduce patient's medical expenses 
from other expensive and invasive diagnostic meth-
ods and its possible complications. For these reasons, 
we were to investigate the clinical significance of se-
rum ferritin in pediatric NAFLD patients as a candi-
date of effective and less-invasive biological marker. 
MATERIALS AND METHODS 
Study design 
　A total of 64 patients diagnosed as NAFLD at Seve-
rance Children’s Hospital, Seoul, Korea, from March 
2010 to February 2013 were included in this study. 
We selected patients whose repetitive alanine amino-
transferase (ALT) was abnormal (30 U/L or more for 
men and 19 U/L or more for women) [12] for un-
known reasons in the regular check-up. Patients with 
ALT elevation for certain reasons (e.g., hepatitis B, 
250　　　　Vol. 17, No. 4, December 2014
Pediatr Gastroenterol Hepatol Nutr
Table 1. Characteristics of Patients of Non-Alcoholic Fatty Liver Disease (NAFLD) Children
Variable Total (n=64) Overweight (n=16) Obese (n=48) p-value
Age
AST (IU/L)
ALT (IU/L)
Albumin (g/dL)
Total bilirubin (mg/dL)
Platelet count (103/μL)
INR
Transferein saturation (%)
Serum iron (μg/dL)
Cholesterol (mg/dL)
Triglyceride (mg/dL)
HDL (mg/dL)
LDL (mg/dL)
MRI 2D PDFF
NAFLD severity markers
　APRI
　AAR 
　FIB-4
13.35 (9.80-20.00)
52.00 (12.00-451.00)
108.50 (16.00-591.00)
4.70 (4.10-5.20)
0.50 (0.20-1.80)
312.00 (189.00-587.00)
0.98 (0.86-1.11)
27.00 (2.00-335.10)
96.00 (11.00-185.00)
189.50 (109.00-374.00)
135.50 (53.00-516.00)
47.00 (25.00-68.00)
118.00 (42.00-178.00)
36.00 (6.00-47.20)
0.40 (0.14-1.92)
0.54 (0.30-1.84)
0.24 (0.11-0.95)
11.70 (10.10-15.10)
49.50 (30.00-101.00)
94.00 (55.00-155.00)
4.70 (4.30-4.90)
0.45 (0.20-0.70)
339.50 (266.00-403.00)
0.98 (0.94-1.11)
29.00 (17.00-316.00)
97.00 (58.00-127.00)
178.00 (155.00-374.00)
175.50 (70.00-289.00)
48.00 (25.00-61.00)
103.20 (81.60-146.00)
32.80 (6.00-47.20)
0.33 (0.24-0.95)
0.52 (0.30-1.84)
0.16 (0.12-0.61)
14.15 (9.80-20.00)
54.00 (12.00-451.00)
120.50 (16.00-591.00)
4.60 (4.10-5.20)
0.50 (0.20-1.80)
303.00 (189.00-587.00)
0.98 (0.86-1.10)
26.50 (2.00-335.10)
95.50 (11.00-185.00)
191.50 (109.00-269.00)
131.50 (53.00-516.00)
47.00 (27.00-68.00)
122.00 (42.00-178.00)
41.20 (22.00-46.60)
0.42 (0.14-1.92)
0.54 (0.30-1.76)
0.26 (0.11-0.95)
<0.0001
0.4023
0.1582
0.8509
0.1004
0.0924
0.3786
0.8038
0.8040
0.9629
0.0909
0.5443
0.1274
0.0194
0.0463
0.7272
0.0010
Values are presented as median (minimum-maximum).
AST: aspartate aminotransferase, ALT: alanine aminotransferase, INR: international normalized ratio, HDL: high density lipoprotein,
LDL: low density lipoprotein, MRI 2D PDFF: magnetic resonance imaging 2-dimensional proton density-fat fraction, APRI: AST
to platelet ratio index, AAR: AST/ALT ratio, FIB-4: fibrosis-4.
hepatitis C, hepatitis A, Wilson’s disease, hemochro-
matosis, etc.) were excluded. No patients in the pop-
ulation reported active substance abuse or significant 
systemic illnesses or were taking drugs known to 
cause hepatic steatosis. All patients had a diagnosis of 
NAFLD based on cryptogenic etiology and MRI-PDFF 
imaging with steatosis ＞5% [7]. Laboratory tests 
(e.g., iron profiles, liver function tests, and lipid pro-
files), MRI PDFF values were obtained from patients’ 
medical records and analyzed. NAFLD severity mark-
ers―such as the aspartate aminotransferase (AST) to 
platelet (PLT) ratio index (APRI), AST/ALT ratio 
(AAR), and fibrosis-4 (FIB-4)―that are known as 
predictors of liver fibrosis were also calculated and 
analyzed [11,13]. 
1. Differences between obese and overweight group
　We aimed to evaluate whether the body mass in-
dex (BMI) influences the variables associated liver 
and serum ferritin. Therefore, we examined the dif-
ferences in the laboratory values, MRI PDFF values 
and NAFLD severity makers between overweight and 
obese groups, which were divided by BMI percentile. 
Obesity was defined as a BMI in the 95th percentile or 
higher, while overweight was defined as a BMI in the 
85th-95th percentile considering age and sex. 
2. Correlation of laboratory values and NAFLD se-
verity markers with serum ferritin level
　To evaluate the significance of serum ferritin level, 
correlation between several liver specific laboratory 
values, MRI 2-dimensional (2D) PDFF and NAFLD 
severity markers with serum ferritin were analyzed. 
Statistical analysis
　Baseline characteristics were presented as the me-
dian and range in parentheses. The obese group and 
overweight group were compared using Mann- 
Whitney U test. Correlations between laboratory and 
serum ferritin were assessed by Spearman analysis. 
For better understanding, the scatter plot of NAFLD 
severity markers was displayed with Spearman cor-
relation coefficient. All tests were two-sided and a 
p-value of 0.05 was considered to be statistically 
significant. Also, statistical analyses were conducted 
with IBM SPSS Statistics version 20.0 (IBM Co., 
www.pghn.org　　　　251
Ji Hoon Na, et al：The Clinical Significance of Serum Ferritin in Pediatric NAFLD
Table 2. Laboratory Value Differences between Obese and Overweight Group
Characteristic Overweight (n=16) Obese (n=48) p-value
AST (IU/L)
ALT (IU/L)
Albumin (g/dL)
Total bilirubin (mg/dL)
Platelet count (109/L)
INR
Transferein saturation (%)
Serum iron (μg/dL)
Ferritin (ng/mg)
Cholesterol (mg/dL)
Triglyceride (mg/dL)
HDL (mg/dL)
LDL (mg/dL)
MRI 2D PDFF
NAFLD severity markers
  APRI 
  AAR 
  FIB-4
54.75±21.55
94.06±28.51
4.66±0.19
0.46±0.14
331.25±41.85
1.00±0.06
45.88±72.41
98.25±19.60
83.21±50.20
199.31±52.91
181.88±80.58
46.06±10.16
109.55±22.63
31.60±11.47
0.42±0.21
0.64±0.46
0.21±0.14
74.33±66.45
135.81±103.93
4.67±0.26
0.63±0.34
308.21±76.47
0.97±0.55
34.31±45.76
97.10±39.16
133.51±114.87
190.77±38.53
149.85±86.51
45.60±7.61
120.60±29.26
39.79±6.27
0.61±0.42
0.60±0.25
0.30±0.16
0.12
0.05
0.50
0.02
0.07
0.06
0.27
0.47
0.03
0.20
0.08
0.20
0.13
0.003
0.04
0.15
0.03
Values are presented as mean±standard deviation.
AST: aspartate aminotransferase, ALT: alanine aminotransferase, INR: international normalized ratio, HDL: high density lipoprotein,
LDL: low density lipoprotein, MRI 2D PDFF: magnetic resonance imaging 2-dimensional proton density-fat fraction, NAFLD: 
non-alcoholic fatty liver disease, APRI: AST to platelet ratio index, AAR: AST/ALT ratio, FIB-4: fibrosis-4.
Armonk, NY, USA). The study was approved by the 
institutional review board of our institution, and it 
was conducted in compliance with the Declaration of 
Helsinki.
RESULTS
Characteristics of pediatric NAFLD patients
　According to the patients’ BMIs, all included pa-
tients were labeled as more than overweight. The 
laboratory test results and patient characteristics of 
the 64 NAFLD patients are presented in Table 1. In 
the table, the patients were divided into two groups, 
obese and overweight, according to their BMI. All 
the variables were described with the median and 
range in parentheses. Other variables shows no sig-
nificant differences except the median value of MRI 
2D PDFF between the two groups (p=0.0194). APRI 
and FIB showed significantly high values in the 
obese group (p=0.0463 and p=0.001, respectively).
1. Differences between obese and overweight group
　There were 48 patients in the obese group and 16 
in the overweight group. As shown in Table 2, the 
values of ALT, total bilirubin, ferritin, and MRI 2D 
PDFF were significantly higher in the obese group 
than the overweight group (p＜0.05). The values of 
the NAFLD severity markers, APRI and FIB-4, were 
0.61±0.42 and 0.30±0.16, respectively, in the obese 
group, which are both significantly higher than the 
corresponding values for the overweight group.
　　　　
2. Correlation between laboratory values and serum 
ferritin
　As shown in Table 3, AST, ALT, international nor-
malized ratio, cholesterol, triglyceride and low den-
sity lipoprotein showed significant correlations with 
serum ferritin. The correlation coefficients of the 
NAFLD severity markers, APRI and FIB-4, were 
0.6682 (0.5014-0.7830) and 0.5876 (0.3956-0.7261) 
respectively, which were statistically significant. AAR 
did not show any significant correlation with serum 
ferritin. Likewise, the scatter plot of APRI and FIB-4 
tended to increase as the serum ferritin increased sig-
nificantly (p＜0.0001 and p＜0.0001, respectively) 
(Fig. 1). In addition, there was a significant correla-
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Table 3. Correlation between Laboratory Values and Serum Ferritin
Variable Correlation coefficient (95% confidence interval) p-value
AST (IU/L)
ALT (IU/L)
Albumin (g/dL)
Total bilirubin (mg/dL)
Platelet count (103/μL)
INR
Transferein saturation (%)
Serum iron (μg/dL)
Cholesterol (mg/dL)
Triglyceride (mg/dL)
HDL (mg/dL)
LDL (mg/dL)
MRI 2D PDFF
BMI (continuous value)
NAFLD severity markers
  APRI 
  AAR 
  FIB-4
0.4529 (0.2296-0.6265)
0.4675 (0.2469-0.6376)
 0.0128 (−0.2338-0.2577)
0.0572 (−0.1917-0.2984)
−0.1258 (−0.3596-0.1249)
−0.2747 (−0.4924-−0.0200)
−0.0063 (−0.2517-0.2399)
0.0195 (−0.2276-0.2639)
0.2777 (0.0320-0.4884)
0.3528 (0.1144-0.5489)
−0.0103 (−0.2554-0.2362)
0.3573 (0.1173-0.5539)
−0.0998 (−0.3385-0.1525)
0.3352 (0.0947-0.5349)
0.6682 (0.5014-0.7830)
0.0386 (−0.2095-0.2815)
0.5876 (0.3956-0.7261)
0.0001
＜0.0001
0.9204
0.6545
0.3234
0.0333
0.9606
0.7892
0.0259
0.0040
0.9359
0.0038
0.4380
0.0065
＜0.0001
0.7628
＜0.0001
AST: aspartate aminotransferase, ALT: alanine aminotransferase, INR: international normalized ratio, HDL: high density lipoprotein,
LDL: low density lipoprotein, MRI 2D PDFF: magnetic resonance imaging 2-dimensional proton density-fat fraction, NAFLD: 
non-alcoholic fatty liver disease, BMI: body mass index, NAFLD: non-alcoholic fatty liver disease, APRI: AST to platelet ratio index,
AAR: AST/ALT ratio, FIB-4: fibrosis-4.
tion between BMI and serum ferritin (Table 3). 
DISCUSSION 
　Recently, NAFLD has become a very important 
disease in the pediatric population. As liver biopsies 
are invasive, reliable and noninvasive biomarkers are 
essential for examining pediatric NAFLD. In this 
study, we examined whether serum ferritin could be 
an effective and less-invasive biological marker that 
could be applied to pediatric patients to predict their 
disease severity. 
　The three-hit hypothesis is the widely known 
NAFLD pathogenesis that a progression to NASH 
and fibrosis depends on additional factors such as 
free fatty acids, inflammatory cytokines and adipo-
kines, oxidative stress, and mitochondrial dysfunc-
tion in the base of obesity and insulin resistance [1]. 
Serum ferritin is the primary tissue for iron-storage 
protein in the liver, where most extra body iron is 
stored. Ferritin levels can be elevated secondary to 
obesity, chronic alcohol consumption, chronic in-
flammation including viral hepatitis, histiocytic neo-
plasm, and steatohepatitis [10]. Hyperferritinemia 
has been previously observed in obesity-related 
chronic inflammatory conditions such as DM, meta-
bolic syndrome, liver cirrhosis, and NAFLD [10]. As 
the ferritin concentration increases, the risk of sig-
nificant liver disease also increases. In NAFLD, in-
creased ferritin levels are considered an expression 
of metabolic syndrome and of hepatic damage, be-
cause of inflammatory cytokine activation [12]. In 
addition, considering the pathophysiology from a 
different standpoint, the histological evidence of 
hepatic iron accumulation has been reported to be 
strongly associated with a hepatic fibrosis in NAFLD 
patients in large multicenter studies [14]. Hepatic 
iron accumulation produces inflammatory cyto-
kines, and they induce hepatic fibrosis [8]. Acco-
rding to another adult study by Kowdley et al. [10], 
the histological features of NAFLD, which include 
steatosis, hepatocellular ballooning, and fibrosis, 
were more severe in patients with increased serum 
ferritin. They concluded that serum ferritin is asso-
ciated with hepatic iron deposition and worsened 
histological activity in patients with NAFLD. However, 
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Fig. 1. (A) Scatter plot between APRI and serum ferritin. 
(B) Scatter plot between AAR and serum ferritin. (C) 
Scatter plot between FIB-4 and serum ferritin. The scatter 
plot of APRI and FIB-4 tended to increase as the serum 
ferritin increased significantly (p<0.0001 and p<0.0001, 
respectively). AST: aspartate aminotransferase, APRI: AST 
to platelet ratio index, ALT: alanine aminotransferase, 
AAR: AST/ALT ratio, FIB-4: fibrosis-4. 
they also said that hyperferritinemia was associated 
with the histologic findings of NAFLD patients 
whose histological findings did not include detect-
able iron deposition. 
　In this study, the MRI 2D PDFF values and liv-
er-related laboratory marker values, including se-
rum ferritin, were higher in the obese group than the 
overweight group, which is concordant with the pre-
vious results of adult studies that indicated that 
NAFLD and NASH are positively correlated with obe-
sity [2,8,15,16]. NAFLD can be divided into five 
grades according to the results of liver biopsy, from 
grade-0 to grade-4. Grade-4 indicates liver cirrhosis. 
According to Permutt et al. [7], the mean MRI 2D 
PDFF value increased significantly with histol-
ogy-determined steatosis grade: ＜5.0% at grade-0, 
5.0-8.9% at grade-1, 8.9-16.3% at grade-2, and 
16.3-25.0% at grade-3; with p≤0.0001. However, no 
significant correlation in the MRI 2D PDFF values at 
grade-4 was found. They thought that this is because 
the results of the MRI 2D PDFF were well correlated 
with low-grade hepatic steatosis, but steatosis was 
not linearly correlated with NAFLD progression. 
Hepatic steatosis may be replaced by collagen in se-
vere NAFLD or cirrhosis. As a result, in severe 
NAFLD or cirrhosis, low hepatic steatosis could be 
found, and there might be no differences between 
MRI 2D PDFF in cirrhosis and MRI 2D PDFF in 
grade-1 steatosis. Therefore, in patients with NAFLD, 
a low amount of hepatic steatosis on imaging may 
not indicate mild NAFLD, so other parameters 
should be considered to distinguish low-grade stea-
tosis from liver cirrhosis [7]. In this study, we tried to 
separate the whole population into five grades 
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(grade 0-4). However, our population was divided 
into two of grade-0, two of grade-1, 11 of grade-2, 
and 51 of grade-3, so there were some limitations to 
our ability to show the relationship between MRI 2D 
PDFF and serum ferritin, because of the largely de-
viated populations of the groups. The reason that the 
correlation between serum ferritin and MRI 2D 
PDFF was not good could be explained as the severity 
of our patients was higher (the median of the MRI 
2D PDFF is 36, the average is 33.68).
　Although liver biopsy remains the gold standard 
for the diagnosis and staging of NASH, we could not 
perform liver biopsies on all patients. Therefore, we 
applied NAFLD severity markers. Using APRI scores, 
McPherson et al. [17] demonstrated an area under 
the receiver operating characteristic curve (AUROC) 
of 0.67 for advanced fibrosis in a study of 145 adult 
NAFLD subjects. The AUROC values for AAR and 
FIB-4 were found to be 0.742 and 0.802, respectively, 
for advanced fibrosis in another study of 541 NAFLD 
patients [18]. In our study, the correlation co-
efficients of APRI and FIB-4 showed 0.6682 (0.5014- 
0.7830) and 0.5876 (0.3956-0.7261), respectively. 
They both showed good statistical correlation with 
serum ferritin (p＜0.0001). These facts suggest the 
clinical usefulness of serum ferritin in pediatric 
NAFLD patients. We think that these NAFLD mark-
ers can make up for some of the limitations of our 
study. By using BMI as a continuous value, we found 
a good correlation with serum ferritin. These results 
show that serum ferritin is correlated with obesity 
and hepatocyte inflammation. 
　The pathophysiology of NAFLD is closely corre-
lated with metabolic syndrome. Obese patients with 
Type 2 DM and NAFLD have been reported to have 
an 80% morbidity rate [19]. Ultrasound examina-
tions are widely implemented as an initial non-in-
vasive diagnostic imaging tool, and some reports in-
dicate that ultrasonography results correlate with 
liver biopsy and liver-related blood test results [20]. 
However, it is an inadequate screening tool, because 
of the large deviation of results according to exam-
iners and the risk of failure in diagnosing early fatty 
liver [11,16,19]. An MRI can provide a significantly 
higher sensitivity and specificity of diagnosis of 
NAFLD: 98% and 99%, respectively. However, pa-
tient compliance is low due to its high cost [5]. This 
is why serum ferritin arouses interest in many adult 
studies as an independent predictor of liver fibrosis. 
According to a study by Manousou et al. [12], serum 
ferritin has relatively high accuracy: 78-85% sensi-
tivity and 60-67% specificity. Although serum ferri-
tin alone is insufficient for diagnosing NAFLD, it 
could be used to rule out NAFLD in those with under-
lying obesity or DM and high serum AST and ALT 
levels. In addition, serum ferritin could be used as a 
marker for NAFLD patients to determine the appro-
priate time to undergo a liver biopsy for the screening 
of NASH or cirrhosis [12,21].   
　In recent studies, Plasma caspase-generated cyto-
keratin-18 fragments (CK-18) as a biological in-
dicator other than serum ferritin were introduced, 
which is indicative of the index of the apoptosis of 
hepatocytes in NASH. It seems to show a high specif-
icity for the diagnosis of NASH in several studies 
[22]. CK-18 is a major intermediate filament protein 
in the liver. Because of obesity-related liver damage, 
injured hepatocytes precede to apoptosis. Then, 
CK-18 fragments are released from hepatocytes and 
can be detected in serum [23,24]. However, accord-
ing to a recent study of the multicenter, Cusi et al. 
[19], Plasma CK-18 was raised significantly with any 
increase in steatosis, inflammation, and fibrosis, but 
because of low sensitivity, there was significant 
vagueness in the prediction of disease severity. 
Therefore, more research is warranted for larger pop-
ulations, to develop simple and non-invasive bio-
logical markers that can provide an alternative for 
the histologic results of liver biopsy. 
　In this study, we applied serum ferritin to pediatric 
NAFLD patients based on previous adult studies. The 
results of the comparison of various liver-related 
tests, MRI findings, and NAFLD severity markers 
showed that serum ferritin was related with the se-
verity of NAFLD. However, due to the limitations of 
the pediatric population, we could not compare the 
liver biopsy tissue of each patient with their serum 
ferritin level. If we could obtain the liver biopsy re-
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sults of the patients divide the patients into several 
grades according to their results, we could describe 
the diagnostic value of the serum ferritin in NAFLD 
patients more precisely; that is the limitation of this 
study. In summary, serum ferritin, as a biological in-
dicator, could have a close correlation with the se-
verity of NAFLD in children. However, when using 
serum ferritin as a noninvasive marker, other factors 
that can affect serum ferritin levels should be co-
ntrolled. 
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